Without new antibiotics, more patients will die from previously treatable infections. A key issue is how the value of antibiotics can be appropriately assessed by payers and HTA bodies.
OHE and RAND Europe were commissioned by the Oxford BRC to undertake a programme of top-down evaluations of aspects of the impact of the BRC. This research looked at the health, economic and scientific impact of Oxford BRC’s research activity.
Resistance to antibiotics is growing. Additional R&D is required. Both Transferable Intellectual Property Rights and Market Entry Rewards should be explored for use in Europe as a regional “pull” incentive.
OHE’s Koonal Shah gave a presentation on the evidence of societal support for an end of life premium at the Pharmaccess Leaders Forum in Milan on 5th May.
OHE’s Yan Feng, Mike Herdman, David Parkin and Nancy Devlin have a new paper in Quality of Life Research to exploring whether patients’ self-reported pain can be compared and aggregated in multi-country studies
OHE’s Professor Nancy Devlin and co-author Richard Brooks have published a new paper that provides an overview of the development of the EQ-5D; the current state of play; and what the future might hold for the further development and use of EQ-5D instruments in HTA and other applications.
